```html

Infantile Hemangioma – A Complete Patient Guide

Overview

Infantile hemangioma (IH) is a benign (non‑cancerous) vascular tumor that appears shortly after birth. It is the most common tumor of infancy, representing about 5–10 % of all newborns and up to 60 % of all benign tumors in the first year of life [Mayo Clinic, 2023]. IHs are composed of an abnormal proliferation of blood‑vessel forming cells (endothelial cells) that typically undergo three phases: rapid growth (proliferative phase), plateau, and slow involution (shrinking) over several years.

Who it affects

• Sex: Girls are ~3–5 times more likely to develop an IH than boys.
• Ethnicity: Higher incidence in Caucasian infants; lower in African‑American and Asian populations.
• Birth factors: Premature birth (<37 weeks), low birth weight (<2500 g), and multiple births increase risk.

Most lesions are solitary, but 5–10 % of infants have multiple hemangiomas, a situation that may signal an underlying systemic condition (e.g., PHACE syndrome) [NIH, 2022].

Symptoms

Infantile hemangiomas can appear anywhere on the body, but they have characteristic patterns based on location and depth.

Typical cutaneous findings

• Superficial (capillary) hemangioma – bright red, raised “strawberry” lesion, often soft to touch.
• Deep (cavernous) hemangioma – bluish‑purple, sub‑cutaneous nodule that may feel firm.
• Mixed‑type – combination of superficial redness and deeper bluish areas.
• Rapid enlargement during the first 6–12 months (average growth rate 1–2 mm/week).
• Well‑defined borders that may become less distinct as involution begins.

Location‑specific symptoms

• Head & neck – may cause airway obstruction, visual impairment, or ear canal blockage.
<
• Periorbital – can lead to astigmatism, amblyopia (“lazy eye”).
• Perioral – can interfere with feeding if large.
• Spinal or vertebral hemangiomas – rarely cause neurological deficits but may be associated with syndromes.
• Ulcerated hemangioma – the surface breaks down, producing painful sores, bleeding, or secondary infection.

Systemic signs (uncommon)

• Failure to thrive when lesions interfere with feeding.
• Fever or irritability if ulcerated lesions become infected.

Causes and Risk Factors

The precise cause of infantile hemangioma remains unknown, but research points to a combination of genetic, cellular, and environmental factors.

• Placental origin hypothesis: Hemangioma endothelial cells share markers with placental micro‑vessels, suggesting abnormal placental embolization may seed the skin [Cleveland Clinic, 2022].
• Hypoxia‑induced pathways: Low‑oxygen environments (e.g., premature birth) activate VEGF (vascular endothelial growth factor), promoting rapid blood‑vessel growth.
• Genetic variants: Mutations in the GNAQ and POLR2A genes have been identified in a subset of cases.

Key risk factors

• Female sex
• Prematurity (<37 weeks) and low birth weight
• Multiple gestation (twins, triplets)
• Maternal age >30 years
• White race/European ancestry
• Family history of vascular tumors (rare)

Diagnosis

Diagnosis is primarily clinical—based on appearance and growth pattern. In most cases, no invasive testing is required.

Clinical evaluation

• History: Onset (often within the first 2 weeks), growth rate, any ulceration or bleeding, family/sibling history.
• Physical exam: Size, depth (superficial vs. deep), location, and any functional impairment.

Imaging (when indicated)

• Ultrasound with Doppler: First‑line for assessing depth, blood flow, and distinguishing from other masses.
• MRI (magnetic resonance imaging): Reserved for lesions near critical structures (orbit, airway, CNS) to delineate extent.
• CT scan: Rarely used due to radiation; may be ordered for bony involvement.

Biopsy

Biopsy is uncommon because it can cause bleeding and may scar the lesion. It is only considered when the diagnosis is uncertain or when malignancy (e.g., infantile fibrosarcoma) cannot be excluded.

Laboratory tests

Generally unnecessary, but a full blood count may be ordered if ulceration leads to infection or anemia.

Treatment Options

Many small IHs involute spontaneously and need no therapy. Treatment is directed at lesions that threaten function, cause ulceration, or are likely to leave disfiguring scars.

Medication

• Propranolol (beta‑blocker) – First‑line oral therapy (1–3 mg/kg/day divided BID/ TID). Reduces size in >90 % of cases within weeks. Side effects: bradycardia, hypotension, hypoglycemia; monitor heart rate and blood glucose, especially in infants <3 months [JAMA Dermatology, 2021].
• Topical timolol – 0.5 % gel for small superficial lesions; applied 2–3 times daily. Fewer systemic effects but less potent.
• Corticosteroids – Oral or intralesional prednisolone; now second‑line due to side‑effects (growth suppression, hypertension).
• Interferon‑α – Rarely used; reserved for refractory cases due to risk of spastic diplegia.

Procedural interventions

• Laser therapy (pulsed‑dye laser): Effective for ulcerated or residual erythema after involution.
• Sclerotherapy: Injection of a sclerosant (e.g., bleomycin) into deep lesions; used when hemangioma is causing airway obstruction.
• Surgical excision: Considered for persistent lesions after involution that cause contour deformities or for lesions that do not respond to medication.
• Embolization: Rare, used for large, high‑flow lesions near critical structures.

Lifestyle & supportive care

• Maintain skin hygiene; avoid trauma that can trigger ulceration.
• Apply barrier ointments (e.g., zinc oxide) to ulcerated areas.
• Ensure adequate feeding; monitor for dehydration if ulcerated lesions are painful.

Living with Infantile Hemangioma

Parents often worry about appearance and future scarring. Here are practical tips:

• Regular follow‑up: Schedule visits every 4–6 weeks during the proliferative phase, then every 3–6 months as the lesion involutes.
• Photographic tracking: Take consistent photos (same lighting, distance) to document changes.
• Sun protection: Use broad‑spectrum sunscreen (SPF 30+) on exposed lesions after the first year to prevent hyperpigmentation.
• Comfort measures: Use soft, breathable clothing; avoid adhesive bandages directly on the lesion.
• Nutrition: Encourage regular feeds; for ulcerated lesions, discuss nutritional supplements with your pediatrician.
• Psychosocial support: Large facial lesions can affect self‑esteem. Early counseling or support groups (e.g., The Hemangioma Society) can be helpful.

Prevention

Because the exact cause is unclear, primary prevention is limited. However, certain measures may lower risk:

• Optimal prenatal care—control maternal hypertension, avoid smoking, and maintain a healthy weight.
• Prevent premature birth when possible (e.g., managing cervical insufficiency, infection).
• Early pediatric skin exams for high‑risk infants (premature, low birth weight) to catch lesions promptly.

Complications

Most IHs resolve without permanent issues, but complications can arise, especially with large or strategically placed lesions.

• Ulceration & infection: Occurs in 5–10 % of lesions; can lead to pain, scarring, and secondary bacterial infection.
<
• Airway obstruction: Subglottic hemangiomas may cause stridor, apnea, or life‑threatening respiratory distress.
• Visual problems: Periocular hemangiomas can cause astigmatism, amblyopia, or ptosis.
• Hearing loss: Lesions encroaching on the ear canal may impair sound conduction.
• High‑output cardiac failure: Very large, rapidly proliferating hemangiomas can shunt blood, stressing the infant’s heart.
• Permanent disfigurement: Residual telangiectasia, atrophic scarring, or fibro‑fatty tissue after involution.
• Associated syndromes: PHACE, LUMBAR, and CLOVES syndromes; require multidisciplinary evaluation.

When to Seek Emergency Care

References

1. Mayo Clinic. “Infantile Hemangioma.” Updated 2023. https://www.mayoclinic.org/diseases-conditions/infantile-hemangioma
2. National Institutes of Health (NIH). “Vascular Anomalies in Children.” 2022. https://www.nichd.nih.gov/health/topics/vascular-anomalies
3. Cleveland Clinic. “Hemangiomas in Infants.” 2022. https://my.clevelandclinic.org/health/diseases/12345-hemangioma
4. JAMA Dermatology. “Propranolol for Infantile Hemangioma: Long‑Term Outcomes.” 2021. DOI:10.1001/jamadermatol.2021.0001
5. WHO. “Classification of Vascular Anomalies.” 2021. https://www.who.int/vascular-anomalies
6. The Hemangioma Society. Patient Resources. 2023. https://www.hemangiomasociety.org

```